65 patents
Utility
Method for Treatment of Rosacea In Patients Aged 35-64 Years
9 Mar 23
A regimen for the therapeutic treatment of rosacea in a subject aged 35-64 years, the regimen comprising topically applying a pharmaceutical composition to the skin of the subject in need of said treatment, the pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in said pharmaceutical composition, wherein said pharmaceutical composition is applied once daily for a period of at least about 2 weeks, at least about 4 weeks, at least about 8 weeks, or at least about 12 weeks, to achieve, in a group of such subjects, a success rate of at least about 12%, at least about 27%, at least about 38%, or at least about 42%, respectively, and wherein the success rate is defined as the number of subjects achieving clear or almost clear skin on the investor global assessment (IGA) scale after treatment with the pharmaceutical composition.
Ofer TOLEDANO, Ofra LEVY-HACHAM, Ori NOV, Vered RAM
Filed: 22 Aug 22
Utility
Treatment of Skin Disorders with Topical Compositions Comprising Tapinarof and a PDE4 Inhibitor
5 Jan 23
Provided herein is a topical combination composition comprising tapinarof, a PDE4 inhibitor and optionally at least one additional active agent selected from a retinoid, benzoyl peroxide (BPO), a Janus kinase inhibitor (JAK inhibitor), a corticosteroid of potency class 1-4, an acaricide and combinations thereof.
Moshe ARKIN, Marcel ZIGHELBOIM, Karine NEIMANN
Filed: 24 Nov 20
Utility
Method for treatment of rosacea
3 Jan 23
A regimen is described for the therapeutic treatment of rosacea.
Moshe Arkin, Karine Neimann, Ofer Toledano
Filed: 3 Dec 21
Utility
Treatment of Cutaneous Adverse Effects Caused by Oncological Therapy with Topical Tapinarof Compositions
8 Dec 22
Provided herein is a topical composition comprising tapinarof and methods of treatment of cutaneous adverse effects caused by oncological therapy with the tapinarof composition.
Moshe ARKIN, Marcel ZIGHELBOIM
Filed: 24 Sep 20
Utility
Method for Long-term Treatment of Rosacea
17 Nov 22
A regimen for the long-term therapeutic treatment of rosacea.
Ofer TOLEDANO, Ofra LEVY-HACHAM, Ori NOV, Vered RAM
Filed: 20 Jul 22
Utility
Treatment of Skin Disorders with Topical Combination Compositions Comprising Tapinarof and an Additional Ahr Activator
20 Oct 22
Provided herein is a topical combination composition comprising tapinarof, an additional AhR activator and optionally further comprising at least one additional active agent selected from a retinoid, benzoyl peroxide (BPO), a Janus kinase inhibitor (JAK inhibitor), a corticosteroid of potency class 1-4, an acaricide and combinations thereof.
Moshe ARKIN, Marcel ZIGHELBOIM
Filed: 24 Sep 20
Utility
Topical Jak Inhibitor Combination Compositions for Treatment of Inflammatory Skin Conditions
15 Sep 22
Provided herein is a topical combination composition and a method of treatment of an inflammatory skin condition by administration of said composition comprising at least one Janus kinase inhibitor (JAK inhibitor) and at least one additional active agent elected from benzoyl peroxide (BPO), at least one retinoid, tapinarof, at least one antibiotic, at least one antiandrogen, at least one acaricide and combinations thereof and a carrier suitable for topical administration.
Moshe ARKIN, Marcel ZIGHELBOIM, Ori NOV, Ofer TOLEDANO
Filed: 23 Jul 20
Utility
Method for long-term treatment of rosacea
30 Aug 22
A regimen for the long-term therapeutic treatment of rosacea.
Ofer Toledano, Ofra Levy-Hacham, Ori Nov, Vered Ram
Filed: 19 Feb 20
Utility
Treatment of Hidradenitis Suppurativa with Tapinarof Compositions
30 Jun 22
The present invention, in some embodiments thereof, relates to treatment of hidradenitis suppurativa by topical or intralesional administration of a composition comprising tapinarof and optionally at least one additional active agent.
Moshe ARKIN
Filed: 26 Mar 20
Utility
Treatment of Rosacea with Topical Combination Compositions
9 Jun 22
Provided herein is a topical combination composition comprising a therapeutically effective amount of at least one acaricidal active agent, a therapeutically effective amount of at least one essentially non-acaricidal anti-inflammatory active agent and a carrier suitable for topical administration for the treatment of rosacea.
Moshe ARKIN
Filed: 19 Mar 20
Utility
Combination of Minocycline and Benzoyl Peroxide and Method of Use Thereof
9 Jun 22
This invention is directed to a regimen administration of combination of minocycline and benzoyl peroxide and uses thereof for treating a skin disorder such as acne or rosacea.
Moshe ARKIN, Karine NEIMANN, Danil FINKEL-MOISEEV
Filed: 19 Mar 20
Utility
Treatment of Skin Disorders with Topical Tapinarof-egfr Inhibitor Compositions
12 May 22
Disclosed are topical compositions and methods of treatment of a skin or mucosal disorder selected from palmoplantar psoriasis, hereditary palmoplantar keratoderma, acquired palmoplantar keratoderma, hydradenitis suppurativa, dermatitis, ichthyosis vulgaris, hereditary ichthyosis, acquired ichthyosis, actinic keratosis, a keratinization skin disorder, a keratinization mucosal disorder, Gorlin syndrome, nail psoriasis, flexural/inverse psoriasis, non-melanoma skin cancer, Cutaneous T-cell lymphoma and precancerous skin, mucosal and nail lesions, by once or twice daily topical administration to a subject of a composition comprising therapeutically effective amount of tapinarof.
Moshe ARKIN, Marcel ZIGHELBOIM, Ori NOV, Ofer TOLEDANO, Karine NEIMANN, Hila HAKAK DJERBI
Filed: 24 Jan 22
Utility
Method for Treatment of Rosacea
5 May 22
A regimen is described for the therapeutic treatment of rosacea.
Moshe ARKIN, Karine NEIMANN, Ofer TOLEDANO
Filed: 3 Dec 21
Utility
Topical Minocycline Foamable Compositions
14 Apr 22
Disclosed are simple yet stable and effective compositions comprising from about 1% to about 5% by weight of the composition of a minocycline or mixtures thereof and pharmaceutically acceptable ingredients comprising from about 60% to about 99% by weight of the composition of at least one hydrophobic oil, and from about 5% to about 25% by weight of the composition of at least one fatty alcohol, wherein the at least one hydrophobic oil and the at least one fatty alcohol are sufficient to ensure the pharmaceutically acceptable assay stability of the minocycline in the composition under 3 months accelerated stability conditions at 40° C./75% RH.
Karine NEIMANN, Danil FINKEL-MOISEEV, Moshe ARKIN, Adina HAIMOV
Filed: 28 Oct 19
Utility
Treatment of Ocular Diseases with Ophthalmic Tapinarof Compositions
10 Mar 22
The present invention relates to the treatment of an ocular inflammatory disease or an ocular degeneration disease by ophthalmic administration of a composition comprising tapinarof and optionally at least one additional active agent.
Moshe ARKIN, Marcel ZIGHELBOIM
Filed: 16 Nov 21
Utility
Method of Treating a Skin Disorder with Egfr Inhibitor
3 Mar 22
The present invention, in some embodiments, relates to a method of treatment, prevention or alleviation of Palmoplantar Keratoderma (PPK) or Olmsted syndrome in a patient in need thereof, comprising a debridement step followed by topical administration of a composition comprising at least one Epidermal Growth Factor Receptor (EGFR) inhibitor.
Moshe ARKIN, Marcel ZIGHELBOIM, Ofra LEVY-HACHAM, Ori NOV
Filed: 9 Nov 21
Utility
Treatment of Psoriasis with Topical Tapinarof-tazarotene Combination Compositions
24 Feb 22
Provided herein is a topical combination composition comprising from about 0.25% w/w to about 2.0% w/w tapinarof, from about 0.025% w/w to about 0.1% w/w tazarotene and a carrier suitable for topical administration.
Moshe ARKIN
Filed: 25 Feb 20
Utility
High Purity Cantharidin Manufacturing Process and Compositions
27 Jan 22
Disclosed are topical compositions and methods of treatment of skin disorders selected from Molluscum contagiosum, verrucae and warts by topical administration to a subject in need thereof of a composition comprising between about 0.5%-1.0% w/w high-purity cantharidin.
Stephen CHERKEZ
Filed: 26 Jul 21
Utility
Treatment of Skin Disorders with Topical Tapinarof Combination Compositions
13 Jan 22
Provided herein are topical combination compositions comprising a therapeutically effective dose of tapinarof and a therapeutically effective dose of at least one additional active agent, selected from at least one corticosteroid, calcipotriene, at least one JAK inhibitor and combinations thereof, and a carrier suitable for topical administration.
Moshe ARKIN
Filed: 27 Jan 20
Utility
Stabilized Microcapsules, Method of Their Preparation and Uses Thereof
25 Nov 21
The present application is directed to stabilized core-shell microcapsules comprising a core of benzoyl peroxide (BPO) or all trans retinoic acid (ATRA) and a metal-oxide shell; and to pharmaceutical compositions and methods of use thereof.
Ofer TOLEDANO, Karine NEIMANN, Danil FINKEL-MOISEEV, Maya ERLICH, Dorit MARCO
Filed: 23 May 21